Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Dendreon Laughs Last
- The Burrill Report submits: What a long, strange trip it’s been for Dendreon DNDN. Three years ago, positive results from a trial of Provenge, its immune therapy drug for prostate cancer, prompted an FDA advisory panel to recommend that...
- External links 2009-05-19
- China Is Growth Market for Novartis
- The Burrill Report submits: The Swiss pharmaceutical giant Novartis NVS said it will invest $1 billion in China over the next five years including a significant expansion of the company’s biomedical research institute in Shanghai. On the heels of the announcement, the company also said it agreed to acquire...
- External links 2009-11-08
- Lilly Hopes New San Diego Facility Will Be 'a Biotechnology Powerhouse'
- The Burrill Report submits: Pharmaceutical giant Eli Lilly LLY opened a new state-of-the-art biotechnology center in San Diego, part of an ongoing effort by the drugmaker to transform itself into a biotech titan. The move follows a relocation of its Imclone headquarters to a new biopharmaceutical research cluster in...
- External links 2009-11-01
- GE's New Fund Hopes to Help 'Shape the Future of Healthcare'
- The Burrill Report submits: The industrial giant GE plans to boost its already sizable presence in the healthcare arena with the establishment of the “GE Healthymagination Fund,” a $250 million equity fund that will make investments in healthcare technology companies. The fund will invest in companies globally that have...
- External links 2009-10-23
- Little Difference Between Roche's Avastin and Lucentis for Macular Degeneration
- The Burrill Report submits: By Kristi Eaton A new study shows that a cancer drug is no different in effectiveness as a gold standard for macula degeneration. Researchers from Boston University School of Medicine and the VA Boston Healthcare System discovered there was no difference in efficacy between Genentech's...
- External links 2009-10-18
- A Depressed Housing Market: Foreclosures Spark Mental Health Crisis
- The Burrill Report submits: By Kristi Eaton The high number of foreclosures as a result of the collapse of the housing market has become not only a financial problem, but a mental health one as well. A new University of Pennsylvania School of Medicine study...
- External links 2009-08-23
- Ending Pay-For-Delay Generic Drug Deals
- The Burrill Report submits: Stopping manufacturers of brand-name drugs from paying potential generic competitors to stay out of the market would save consumers $3.5 billion a year, says the U.S. Federal Trade Commission. FTC Chairman Jon Leibowitz says that eliminating these so-called “pay-for-delay” settlements between brand and generic pharmaceutical...
- External links 2009-06-26
- No Recession Seen in Medical Costs
- The Burrill Report submits: Driven by increasing use of healthcare and other trends, U.S. medical costs are expected to grow by 9 percent in 2010, once again far outstripping the rise in inflation and employee wages, a new report says. The increase is expected to be lower than the...
- External links 2009-06-21
- Life Science Looks to Big Pharma for Funding as Caution Still Reigns
- The Burrill Report submits: By MARIE DAGHLIAN Last week's flurry of public-share offerings must have been a blip on the radar screen, as most life sciences companies look to private investors for much needed cash. And while the number of PIPEs and venture-capital financings continues at a fairly good...
- External links 2009-06-15
- Ethanol Makers Still Trying to Catch a Break from Banks, Debt Holders
- The Burrill Report submits: by MARIE DAGHLIAN A combination of lower oil prices and challenging financial markets continues to spell disaster for U.S. ethanol companies, with another 10 providers of this first-generation biofuel going belly up in the first five months of 2009. Among the latest was Pacific Ethanol PEIX,...
- External links 2009-06-07
- Exelixis Suggests Creativity in Finding Cash for Biotechs in Rough Times
- The Burrill Report submits: by ERIC WAHLGREN There may be no summer lovin’ for biotechs. By most accounts, investors will remain tight-fisted with their cash for some time, opening up their wallets for only the most promising investments. In a sign of how devastating the global economic crisis has...
- External links 2009-05-26
- Merck, CIGNA Prove It Pays to Be Healthy
- The Burrill Report submits: Aware of recent studies which showed that paying people to lose weight and quit smoking actually works, CIGNA CI and Merck MRK have decided to launch a program that pays CIGNA beneficiaries to improve their diabetes control. And if they happen to take Merck’s...
- External links 2009-05-22
- Disney Aiming to Crack Pre-Teen Boys Market
- The Burrill Report submits: The Walt Disney Company DIS wants a bigger piece of the action in the pre-teen boy market, so it hired an anthropologist to sort through the dresser drawers of a 12 year-old. Venturing into territory never before seen by human eyes, much less smelled by...
- External links 2009-05-20
- Biotech Blooms at Eli Lilly
- The Burrill Report submits: Pharmaceutical giant Eli Lilly LLY opened a new state-of-the-art biotechnology center in San Diego, part of an ongoing effort by the drugmaker to transform itself into a biotech titan. The move follows a relocation of its ImClone headquarters to a new biopharmaceutical research cluster in...
- External links 2009-11-08
Additional Resources
- Biotechs Enter a "Dark Age" as Cash Runs Out
- Twenty-three biotech companies have pulled their planned IPOs this year, according to The Burrill Biotechnology Report. The companies are now looking for partnerships with Big Pharma or to be acquired. The situation is essentially a race against time for dozens of companies as they try to find new funding before...
- Blog posts 2008-11-28
- Scynexis. (Regional Report: Triangle).(Brief Article)
- RESEARCH TRIANGLE PARK -- Scynexis has raised $29 million in venture capital. Among the drug company's investors were Alta Partners and Burrill & Co., both in San Francisco. Scynexis also announced that it will collaborate with New Jersey-based Merck, a large drug maker, to develop infection-fighting...
- Research articles 2002-09-01
- The Biotech Industry Finally Turns a Profit
- They say that nobody should start a company to make money. Here's proof: for all the buzz about biotech, in 40 years (really, 42, since Genentech's founding in 1976), the biotech industry as a whole never made a profit -- until last year. Drawing on data from publicly-traded companies, Peter...
- Blog posts 2009-02-23
- Biotech Finally Posts a Profit
- They say that nobody should start a company to make money. Here's proof: for all the buzz about biotech, in 40 years (really, 42, since Genentech's founding in 1976), the biotech industry as a whole never made a profit -- until last year. Drawing on data from publicly-traded companies, Peter...
- Blog posts 2009-02-23
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
